tyrosine kinase inhibitors
So far, non-selective tyrosine kinase inhibitors (TKIs) have shown a minor benefit in HER2-mutant NSCLC patients.
So far, non-selective tyrosine kinase inhibitors ( TKIs ) have shown a minor benefit in HER2-mutant NSCLC patients .